In pulmonary adenocarcinoma and liver cancers, decreased expression of ANXA2 after ANXA2 knock-down was followed by decreased expression of MMP2, as well as decreased proliferation, migration and invasion ability [43, 44]. This evidence concerns the gene MMP2 and liver cancer.